Nicola Beltraminelli Email & Phone Number

Caluire-et-Cuire, FR

Marseille, Provence-Alpes-Côte d’Azur, FR

Innate Pharma S.A. is a clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.Responsibilities:- Global supervision of the Research & Early Development (RED) activities of the company, including NBE discovery and.

Marseille, Provence-Alpes-Côte d’Azur, FR

Innate Pharma S.A. is a clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.Responsibilities:- Global supervision of the non-clinical development activities company wide including safety, bioanalytical, supply and.

Lysogene is a public company aiming at developing novel gene therapies against neurological disorders. Lysogene’s lead programs are in neurodegenerative lysosomal storage disorders that affect children.Responsibilities: - Global supervision of the CMC activities for the late-stage development of 2 assets (Phase 1-2-3 and Phase 2-3) with the objective to.

Cambridge, Massachusetts, US

Scientific supervision of the French Immuno-Oncology Research activities including: - The selection of new immuno-oncology targets - The definition of a general work plan for each project, as well as for the French research site with objectives, deliverables, go/no go decision points, and budget - The antibody discovery activities leading to the isolation.

Cambridge, Massachusetts, US

My role covers a global position over the Paris, China and Cambridge-US sites, including the management of teams in the US, China and Paris sites (15 headcounts)Activities: - Design of immunizations strategies for the discovery of antibodies- Characterization of monoclonal antibodies along their development path including but not limited to: - In silico.

Cambridge, Massachusetts, US

My role covers a global leading position over the Paris, China and Cambridge-US sites on antibody protein science, binding/functional assays development activities, as well as all CMC activitiesThe activities are structured as follows: - Management of the US, China and Paris teams (15 headcounts)- Characterization of monoclonal antibodies along their.

Company OverviewBliNK Biomedical is a therapeutic antibody company focused on immune-oncology. The company has been founded in January 2015 from the assets of the Valneva antibody discovery platform (in Lyon) and the shareholders of BliNK Therapeutics Ltd in Stevenage, UK.The company leverage its B cell technology to develop proprietary antibody programs.

The main goals of the VIVA|Screen platform are:- Discovery of antibodies for customers (infectious diseases and autologous targets) until the early preclinical phase- Research and discovery of antibodies for proprietary programs until late preclinical phase- Continuous optimization of the platform development

FR

Vivalis’s VIVA|Screen® technology enables the discovery of fully human therapeutic antibodies. Based on the combination of Humalex®, a technology enabling to immortalize human B-lymphocytes producing antibodies from selected donors exposed to the pathology of interest and ISAAC, a novel technology enabling to screen individual B lymphocytes on microarray.

FR

The main goals of this department are:- Develop the EB66 plateform (avian cell line producing monoclonal antibodies with superior ADCC activity) by increasing the productivity of the cell line - Obtain producing cells of the candidate product (monoclonal antibody or recombinant protein) for clients and/or for the internal pipelineMy activities covered also.

Supervision of a 7 person team for the process dev of 2 glycoproteins of 192kDa and 272kDa. The work was divided as follows:1 Construction of the plasmid, cloning in CHO, screening and selection of clones to obtain a pre-MCB2 Screening of media and cell culture parameters in bioreactors 3 Dev of DSP steps (IEX, HIC,SEC, TFF) including viral removal/inact..

The goal was to produce recombinant proteins for new vaccines to be tested in preclinical trials, as well as for customers asking for pure proteins at mg amounts. The recombinant proteins were produced and purified with amounts ranging from 2 mg to 20 mg. Most of them (glycosylated) have been produced in the 293T mammalian line, the rest in E. coli..

Ph.D, Biochemistry

Education record

Education record

Diplom Bio Ii